BANGALORE, India, January 27 /PRNewswire-FirstCall/ -- Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.
The year-old partnership focuses on Jubilant delivering preclinical candidates in the therapeutic area of oncology. Endo owns the late-stage development and commercialization rights for molecules discovered in the partnership. Jubilant derives research funding and success-based development and commercialization milestones.
Commenting on this development, Sri Mosur, CEO & President, Global Drug Discovery & Development said: "We are pleased that we could deliver early success to the discovery portfolio efforts at Endo Pharmaceuticals and this expansion is a testimony to Jubilant's focus in building world class oncology capabilities, among other therapeutic areas. This collaboration further reinforces the concept of globally leveraged R&D that creates a platform for scientists from Endo and Jubilant to collaborate in finding affordable remedies for cancer patients worldwide."
"We have been impressed by the quality of the science and the progress made to date by the Jubilant team on our ongoing oncology discovery program, said Dr. Ivan Gergel, M.D, Executive Vice President of R&D at Endo Pharmaceuticals. "Expanding our relationship in this important therapeutic area is consistent with our strategy of building Endo's pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts."
About Jubilant Biosys
Jubilant Biosys Ltd.
|SOURCE Jubilant Biosys Ltd|
Copyright©2010 PR Newswire.
All rights reserved